Cargando…

Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials

Objective To test the efficacy of supplemental vitamin D and active forms of vitamin D with or without calcium in preventing falls among older individuals. Data sources We searched Medline, the Cochrane central register of controlled trials, BIOSIS, and Embase up to August 2008 for relevant articles...

Descripción completa

Detalles Bibliográficos
Autores principales: Bischoff-Ferrari, H A, Dawson-Hughes, B, Staehelin, H B, Orav, J E, Stuck, A E, Theiler, R, Wong, J B, Egli, A, Kiel, D P, Henschkowski, J
Formato: Texto
Lenguaje:English
Publicado: BMJ Publishing Group Ltd. 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755728/
https://www.ncbi.nlm.nih.gov/pubmed/19797342
http://dx.doi.org/10.1136/bmj.b3692
_version_ 1782172456629305344
author Bischoff-Ferrari, H A
Dawson-Hughes, B
Staehelin, H B
Orav, J E
Stuck, A E
Theiler, R
Wong, J B
Egli, A
Kiel, D P
Henschkowski, J
author_facet Bischoff-Ferrari, H A
Dawson-Hughes, B
Staehelin, H B
Orav, J E
Stuck, A E
Theiler, R
Wong, J B
Egli, A
Kiel, D P
Henschkowski, J
author_sort Bischoff-Ferrari, H A
collection PubMed
description Objective To test the efficacy of supplemental vitamin D and active forms of vitamin D with or without calcium in preventing falls among older individuals. Data sources We searched Medline, the Cochrane central register of controlled trials, BIOSIS, and Embase up to August 2008 for relevant articles. Further studies were identified by consulting clinical experts, bibliographies, and abstracts. We contacted authors for additional data when necessary. Review methods Only double blind randomised controlled trials of older individuals (mean age 65 years or older) receiving a defined oral dose of supplemental vitamin D (vitamin D(3) (cholecalciferol) or vitamin D(2) (ergocalciferol)) or an active form of vitamin D (1α-hydroxyvitamin D(3) (1α-hydroxycalciferol) or 1,25-dihydroxyvitamin D(3) (1,25-dihydroxycholecalciferol)) and with sufficiently specified fall assessment were considered for inclusion. Results Eight randomised controlled trials (n=2426) of supplemental vitamin D met our inclusion criteria. Heterogeneity among trials was observed for dose of vitamin D (700-1000 IU/day v 200-600 IU/day; P=0.02) and achieved 25-hydroxyvitamin D(3) concentration (25(OH)D concentration: <60 nmol/l v ≥60 nmol/l; P=0.005). High dose supplemental vitamin D reduced fall risk by 19% (pooled relative risk (RR) 0.81, 95% CI 0.71 to 0.92; n=1921 from seven trials), whereas achieved serum 25(OH)D concentrations of 60 nmol/l or more resulted in a 23% fall reduction (pooled RR 0.77, 95% CI 0.65 to 0.90). Falls were not notably reduced by low dose supplemental vitamin D (pooled RR 1.10, 95% CI 0.89 to 1.35; n=505 from two trials) or by achieved serum 25-hydroxyvitamin D concentrations of less than 60 nmol/l (pooled RR 1.35, 95% CI 0.98 to 1.84). Two randomised controlled trials (n=624) of active forms of vitamin D met our inclusion criteria. Active forms of vitamin D reduced fall risk by 22% (pooled RR 0.78, 95% CI 0.64 to 0.94). Conclusions Supplemental vitamin D in a dose of 700-1000 IU a day reduced the risk of falling among older individuals by 19% and to a similar degree as active forms of vitamin D. Doses of supplemental vitamin D of less than 700 IU or serum 25-hydroxyvitamin D concentrations of less than 60 nmol/l may not reduce the risk of falling among older individuals.
format Text
id pubmed-2755728
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BMJ Publishing Group Ltd.
record_format MEDLINE/PubMed
spelling pubmed-27557282009-12-02 Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials Bischoff-Ferrari, H A Dawson-Hughes, B Staehelin, H B Orav, J E Stuck, A E Theiler, R Wong, J B Egli, A Kiel, D P Henschkowski, J BMJ Research Objective To test the efficacy of supplemental vitamin D and active forms of vitamin D with or without calcium in preventing falls among older individuals. Data sources We searched Medline, the Cochrane central register of controlled trials, BIOSIS, and Embase up to August 2008 for relevant articles. Further studies were identified by consulting clinical experts, bibliographies, and abstracts. We contacted authors for additional data when necessary. Review methods Only double blind randomised controlled trials of older individuals (mean age 65 years or older) receiving a defined oral dose of supplemental vitamin D (vitamin D(3) (cholecalciferol) or vitamin D(2) (ergocalciferol)) or an active form of vitamin D (1α-hydroxyvitamin D(3) (1α-hydroxycalciferol) or 1,25-dihydroxyvitamin D(3) (1,25-dihydroxycholecalciferol)) and with sufficiently specified fall assessment were considered for inclusion. Results Eight randomised controlled trials (n=2426) of supplemental vitamin D met our inclusion criteria. Heterogeneity among trials was observed for dose of vitamin D (700-1000 IU/day v 200-600 IU/day; P=0.02) and achieved 25-hydroxyvitamin D(3) concentration (25(OH)D concentration: <60 nmol/l v ≥60 nmol/l; P=0.005). High dose supplemental vitamin D reduced fall risk by 19% (pooled relative risk (RR) 0.81, 95% CI 0.71 to 0.92; n=1921 from seven trials), whereas achieved serum 25(OH)D concentrations of 60 nmol/l or more resulted in a 23% fall reduction (pooled RR 0.77, 95% CI 0.65 to 0.90). Falls were not notably reduced by low dose supplemental vitamin D (pooled RR 1.10, 95% CI 0.89 to 1.35; n=505 from two trials) or by achieved serum 25-hydroxyvitamin D concentrations of less than 60 nmol/l (pooled RR 1.35, 95% CI 0.98 to 1.84). Two randomised controlled trials (n=624) of active forms of vitamin D met our inclusion criteria. Active forms of vitamin D reduced fall risk by 22% (pooled RR 0.78, 95% CI 0.64 to 0.94). Conclusions Supplemental vitamin D in a dose of 700-1000 IU a day reduced the risk of falling among older individuals by 19% and to a similar degree as active forms of vitamin D. Doses of supplemental vitamin D of less than 700 IU or serum 25-hydroxyvitamin D concentrations of less than 60 nmol/l may not reduce the risk of falling among older individuals. BMJ Publishing Group Ltd. 2009-10-01 /pmc/articles/PMC2755728/ /pubmed/19797342 http://dx.doi.org/10.1136/bmj.b3692 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Research
Bischoff-Ferrari, H A
Dawson-Hughes, B
Staehelin, H B
Orav, J E
Stuck, A E
Theiler, R
Wong, J B
Egli, A
Kiel, D P
Henschkowski, J
Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
title Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
title_full Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
title_fullStr Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
title_full_unstemmed Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
title_short Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials
title_sort fall prevention with supplemental and active forms of vitamin d: a meta-analysis of randomised controlled trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755728/
https://www.ncbi.nlm.nih.gov/pubmed/19797342
http://dx.doi.org/10.1136/bmj.b3692
work_keys_str_mv AT bischoffferrariha fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT dawsonhughesb fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT staehelinhb fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT oravje fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT stuckae fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT theilerr fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT wongjb fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT eglia fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT kieldp fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials
AT henschkowskij fallpreventionwithsupplementalandactiveformsofvitamindametaanalysisofrandomisedcontrolledtrials